Targeting HER2 expression in cancer: New drugs and new indications
Functional activation of human epidermal growth factor receptor 2 (HER2) has been shown to strongly promote carcinogenesis, leading to the investigation of HER2-directed agents in cancers with HER2 genomic alterations. This has been best documented in the context of HER2 gene amplification in breas...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
2021-02-01
|
| Series: | Biomolecules & Biomedicine |
| Subjects: | |
| Online Access: | https://www.bjbms.org/ojs/index.php/bjbms/article/view/4908 |
| _version_ | 1797261302352052224 |
|---|---|
| author | Semir Vranić Semir Bešlija Zoran Gatalica |
| author_facet | Semir Vranić Semir Bešlija Zoran Gatalica |
| author_sort | Semir Vranić |
| collection | DOAJ |
| description |
Functional activation of human epidermal growth factor receptor 2 (HER2) has been shown to strongly promote carcinogenesis, leading to the investigation of HER2-directed agents in cancers with HER2 genomic alterations. This has been best documented in the context of HER2 gene amplification in breast and gastric/gastroesophageal junction carcinomas for which several HER2-directed agents are available and have become a part of standard treatment regimens. Somatic HER2 gene mutations have been recently described at low frequency in a variety of human cancers and have emerged as a novel predictive biomarker for HER2-directed therapies. Preclinical data also indicate that activating HER2 mutations are potent oncogenic drivers in a manner that is analogous to HER2 amplification. HER2 mutations may clinically confer sensitivity to HER2-directed agents as recently shown in a phase II clinical trial with antibody-drug conjugate against HER2 trastuzumab deruxtecan in patients with non-squamous non-small cell lung carcinoma.
|
| first_indexed | 2024-04-24T23:39:03Z |
| format | Article |
| id | doaj.art-73aeb8f9793a4d63b56a42678e46a461 |
| institution | Directory Open Access Journal |
| issn | 2831-0896 2831-090X |
| language | English |
| last_indexed | 2024-04-24T23:39:03Z |
| publishDate | 2021-02-01 |
| publisher | Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina |
| record_format | Article |
| series | Biomolecules & Biomedicine |
| spelling | doaj.art-73aeb8f9793a4d63b56a42678e46a4612024-03-15T13:42:33ZengAssociation of Basic Medical Sciences of Federation of Bosnia and HerzegovinaBiomolecules & Biomedicine2831-08962831-090X2021-02-0121110.17305/bjbms.2020.4908Targeting HER2 expression in cancer: New drugs and new indicationsSemir Vranić0https://orcid.org/0000-0001-9743-7265 Semir Bešlija1https://orcid.org/0000-0002-3066-3871Zoran Gatalica2College of Medicine, QU Health, Qatar University, Doha, QatarDepartment of Oncology, Clinical Center of the University of Sarajevo, Sarajevo, Bosnia and HerzegovinaCreighton University School of Medicine, Phoenix, Arizona, United States and Oklahoma University College of Medicine, Oklahoma City, Oklahoma, United States Functional activation of human epidermal growth factor receptor 2 (HER2) has been shown to strongly promote carcinogenesis, leading to the investigation of HER2-directed agents in cancers with HER2 genomic alterations. This has been best documented in the context of HER2 gene amplification in breast and gastric/gastroesophageal junction carcinomas for which several HER2-directed agents are available and have become a part of standard treatment regimens. Somatic HER2 gene mutations have been recently described at low frequency in a variety of human cancers and have emerged as a novel predictive biomarker for HER2-directed therapies. Preclinical data also indicate that activating HER2 mutations are potent oncogenic drivers in a manner that is analogous to HER2 amplification. HER2 mutations may clinically confer sensitivity to HER2-directed agents as recently shown in a phase II clinical trial with antibody-drug conjugate against HER2 trastuzumab deruxtecan in patients with non-squamous non-small cell lung carcinoma. https://www.bjbms.org/ojs/index.php/bjbms/article/view/4908HER2targeted therapymutationsamplification |
| spellingShingle | Semir Vranić Semir Bešlija Zoran Gatalica Targeting HER2 expression in cancer: New drugs and new indications Biomolecules & Biomedicine HER2 targeted therapy mutations amplification |
| title | Targeting HER2 expression in cancer: New drugs and new indications |
| title_full | Targeting HER2 expression in cancer: New drugs and new indications |
| title_fullStr | Targeting HER2 expression in cancer: New drugs and new indications |
| title_full_unstemmed | Targeting HER2 expression in cancer: New drugs and new indications |
| title_short | Targeting HER2 expression in cancer: New drugs and new indications |
| title_sort | targeting her2 expression in cancer new drugs and new indications |
| topic | HER2 targeted therapy mutations amplification |
| url | https://www.bjbms.org/ojs/index.php/bjbms/article/view/4908 |
| work_keys_str_mv | AT semirvranic targetingher2expressionincancernewdrugsandnewindications AT semirbeslija targetingher2expressionincancernewdrugsandnewindications AT zorangatalica targetingher2expressionincancernewdrugsandnewindications |